Question explored with the scientific record
Do statins reduce cardiovascular events and mortality in primary vs secondary prevention?
Statins clearly reduce cardiovascular events and mortality in secondary prevention, but the benefit in primary prevention is smaller, age-dependent, and more contested.
The evidence for secondary prevention is strong and consistent. In patients who already have heart disease or have had a stroke, statins cut the risk of another major event. The 4S trial found simvastatin reduced overall mortality by 30% in people with established coronary heart disease [2]. A large meta-analysis of 14 trials found statins reduced all-cause mortality by about 24% (odds ratio 0.76) [6]. In older adults with prior cardiovascular disease, the benefit holds: pravastatin reduced the primary endpoint by 22% in the PROSPER trial [9], and a real-world study of older UK patients found statins after a heart attack reduced mortality by about 38% (HR 0.62) [8].
The evidence for primary prevention is weaker and the absolute benefit is small. A meta-analysis of 21 trials found statins reduced all-cause mortality by only 0.8% in absolute terms [7]. In the JUPITER trial, rosuvastatin reduced major events in healthy people with elevated CRP, but the trial was stopped early and the absolute benefit was modest [5]. In older adults, the picture is mixed: a large Israeli cohort found statins reduced MACE in people over 70 (HR 0.71) [1], but the CTT meta-analysis found no significant reduction in major vascular events for primary prevention patients over 75 [9]. The HOPE-3 trial found no mortality benefit from rosuvastatin in intermediate-risk adults [7].
| Population | All-cause mortality reduction | Key source |
|---|---|---|
| Secondary prevention (established CVD) | ~24% relative (OR 0.76) | Meta-analysis of 14 trials [6] |
| Secondary prevention (post-heart attack, older) | ~38% relative (HR 0.62) | UK cohort [8] |
| Primary prevention (general) | 0.8% absolute | Meta-analysis of 21 trials [7] |
| Primary prevention (over 75) | Not significant | CTT meta-analysis [9] |
The harms are real but uncommon. Statins increase the risk of new-onset diabetes by about 9-13% [3], and muscle symptoms are common. In one study of physically active military personnel, statin use was linked to higher diabetes risk without clear cardiovascular benefit [4]. The risk-benefit calculus is very different for a 50-year-old with no heart disease than for a 65-year-old who has already had a heart attack.
My call: statins are worth taking for secondary prevention in most people with established cardiovascular disease. For primary prevention, the benefit is small enough that the decision should be individual, factoring in age, diabetes risk, and the person's own values. Confidence: high for secondary prevention, moderate for primary prevention.
Sources used 9
-
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
An Overview of the Impact of Statin Therapy on Cardiac Incident Risk
This narrative review summarizes evidence that statin therapy lowers LDL cholesterol and reduces major cardiovascular events in primary and secondary prevention, while noting muscle symptoms and a modest increased risk of type 2 diabetes as adverse effects.
DOI: 10.12775/qs.2025.38.58289 -
Adverse effects of statin therapy and their treatment
A narrative review summarizing the adverse effects of statin therapy (hepatic dysfunction, myopathy, and diabetes risk) and their management, comparing major international guidelines and offering practical recommendations.
DOI: 10.36011/cpp.2022.4.e4 -
Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?
This study investigates the association between statin use and cardiovascular outcomes as well as adverse events, particularly diabetes, in physically active military personnel, finding that statin use is linked to increased diabetes risk without significant cardiovascular benef…
DOI: 10.1016/j.jsams.2016.12.075 -
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease
The Jupiter study demonstrated that rosuvastatin significantly reduces cardiovascular events and all-cause mortality in apparently healthy individuals with elevated C-reactive protein levels, suggesting the need for statin therapy in this population.
DOI: 10.1177/1753944709337056 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
Statin Use and the Risk of All-cause Mortality
Statins reduced all-cause mortality in some trials, but a meta-analysis found only a 0.8% absolute reduction, leaving the effect uncertain and prompting calls for trials with all-cause mortality as the primary endpoint.
DOI: 10.3904/kjm.2023.98.1.4 -
Safety and Effectiveness of Statins for Prevention of Recurrent Myocardial Infarction in 12 156 Typical Older Patients: A Quasi-Experimental Study
Statins after myocardial infarction in a large real-world cohort of older UK patients reduce recurrent MI and all-cause mortality in 60–79-year-olds, show no clear recurrence benefit in 80+, and are linked to higher falls and fractures among the oldest, with age-dependent cost i…
DOI: 10.1093/gerona/glw082 -
Statin Therapy for Primary and Secondary Prevention in Older Adults
Evidence supports statin therapy for secondary prevention in older adults and for primary prevention in selected high-risk older patients; age alone should not deter statin therapy.
DOI: 10.1007/s11883-024-01257-9